Woodline Partners LP Has $11.20 Million Stock Position in Insmed Incorporated (NASDAQ:INSM)

Woodline Partners LP lessened its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 25.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 162,230 shares of the biopharmaceutical company's stock after selling 54,149 shares during the period. Woodline Partners LP owned about 0.09% of Insmed worth $11,200,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC increased its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the period. Spire Wealth Management acquired a new position in Insmed in the fourth quarter worth approximately $47,000. Smartleaf Asset Management LLC increased its holdings in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Insmed in the fourth quarter worth approximately $86,000.

Insmed Stock Performance

INSM stock traded down $0.91 during midday trading on Wednesday, hitting $67.11. The stock had a trading volume of 445,266 shares, compared to its average volume of 2,326,523. The firm has a market capitalization of $12.22 billion, a price-to-earnings ratio of -12.02 and a beta of 0.84. Insmed Incorporated has a 52 week low of $44.51 and a 52 week high of $84.91. The stock has a 50-day simple moving average of $70.24 and a 200 day simple moving average of $72.99. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the business earned ($1.06) earnings per share. As a group, equities research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

INSM has been the topic of a number of research reports. UBS Group dropped their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company increased their price objective on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a report on Wednesday, March 19th. Truist Financial increased their price target on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $94.63.

Insider Buying and Selling

In related news, insider Michael Alexander Smith sold 409 shares of Insmed stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $65.61, for a total value of $26,834.49. Following the completion of the transaction, the insider now directly owns 91,794 shares of the company's stock, valued at $6,022,604.34. The trade was a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Martina M.D. Flammer sold 9,925 shares of Insmed stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $65.47, for a total value of $649,789.75. Following the completion of the transaction, the insider now directly owns 86,596 shares of the company's stock, valued at $5,669,440.12. This represents a 10.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 153,098 shares of company stock valued at $10,724,192 over the last ninety days. 3.00% of the stock is owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.